Saturday 18 August 2018
Contact US    |    Archive
Stony Brook
11 days ago

First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. T

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.

Polo Caxias tem novo endereço

- Federal do Rio de Janeiro
Hashtags:   

First

 | 

Human

 | 

Clinical

 | 

Trial

 | 

Targeting

 | 

CD4

 | 

Protein

 | 

for

 | 

Aggressive

 | 

cell

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Polo Caxias tem novo endereço

- Federal do Rio de Janeiro

Most Popular (a week)